echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The biggest winner of consistency evaluation in 2019: Qilu pharmaceutical

    The biggest winner of consistency evaluation in 2019: Qilu pharmaceutical

    • Last Update: 2020-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Original: vernacular According to pharmago database, there are 6 enterprises that have passed the consistency evaluation in 2019, including Qilu pharmaceutical, Yangzi River, Shiyao group, Zhengda Tianqing, Kelun pharmaceutical and Fosun Pharmaceutical Among them, Qilu Pharmaceutical Co., Ltd has 17 drugs passed the consistency evaluation in 2019, becoming the biggest winner in 2019 In addition, paclitaxel (albumin) is the third injection after Hengrui and Ouyi At present, the drug has been listed in the second batch of national centralized purchase list In the first round of national centralized mining, Qilu pharmaceutical has a strong performance, and all five varieties (gefitinib, risperidone, atorvastatin, olanzapine and tenofovir ester) have won the bid, with a price reduction of 49% - 78% In the second batch of national centralized procurement list released recently, Qilu pharmaceutical is currently qualified to participate in the bidding of 6 varieties, including adefovir dipivoxil tablets, trimetazidine hydrochloride sustained-release tablets, solinacin Succinate Tablets, tadalafil tablets, tegio capsules and paclitaxel for injection (albumin binding type) In 2019, 14 drugs from Yangzijiang Pharmaceutical Co., Ltd and Shiyao group passed the consistency evaluation, ranking second Among them, Yangzi River includes omeprazole enteric coated capsule, which is the first high difficulty product that has been evaluated In the first round of national centralized mining, two exclusive evaluated varieties (enalapril maleate tablets and dexmedetomidine hydrochloride injection) from Yangzi River won the bid, and the price was the same as the previous 4 + 7 bid price In the second round of centralized procurement list released this time, the drugs that Yangzi River is currently eligible to participate in the bidding include fluconazole tablets, Cefalexin Capsules, meloxicam tablets and cefradine capsules The drugs eligible for bidding are Amoxicillin Capsules and clindamycin hydrochloride capsules.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.